Pre-emption Group Guidelines meaning

In this issue: Judicial College Guidelines, 17th Edition now available on Lexis+ CPR updates Clinical negligence Evidence and disclosure Costs Other PI and Clinical Negligence News LexTalk® PI & Clinical Negligence: a Lexis®Nexis community Daily and weekly news alerts Judicial College Guidelines, 17th Edition now available on Lexis+ The seventeenth edition of the Judicial College Guidelines (JCG) is now accessible on Lexis+. Locate it through Butterworths Personal Injury Litigation Service (BPILS), Division IX, Quantum Summaries. See: Butterworths Personal Injury Litigation Service, Division IX, Quantum Summaries CPR updates 165th Practice Direction update—in force 6 April 2024 The Master of the Rolls and the Parliamentary Under-Secretary of State for Justice have signed off the 165th Practice Direction (PD) update to the Civil Procedure Rules (CPR). This PD introduces changes allowing VAT to be recovered within fixed recoverable costs (FRC) for disbursements in restoration proceedings under CPR 45.15A, as well as for pre-action and...

In this issue: UK, EU and international regulators and bodies Accountability, culture and social governance Prudential rules Risk oversight and controls Financial crime and sanctions Complaints, redress and claims handling Investigations, enforcement and discipline Capital markets oversight Derivatives regulation Banks and mutuals Investment funds and asset management EU MiFID II Insurance regulation Payment services and systems Fintech and cryptoassets AI regulation in financial services Financial Services Enforcement Database Intraday news alerts Daily and weekly news alerts New and updated content Dates for your diary UK, EU and international regulators and bodies MPs raise deep-rooted problems at FCA in critical report Law360, London: A forthcoming report from a cross-party group of MPs is set to underscore shortcomings in how the Financial Conduct Authority (FCA) addresses major scandals, notwithstanding its attempts to reshape culture and operations, according to early details issued on 25 November...

No medicinal product can be marketed until it has obtained approval known as a marketing authorisation (MA). An MA specifies the authorised indications, the patient population and the dosage, together with any conditions placed on the MA holder (MAH). The approval framework is regulated by Directive 2001/83/EC on the Community Code relating to medicinal products for human use (the Pharmaceutical Code). There are several routes to secure an MA for medicinal products: EU centralised procedure (CP), with medicines approved via the CP often termed centrally authorised products (CAPs) Mutual recognition procedure (MRP) Decentralised procedure (DCP) National procedure The appropriate route is determined by the product’s nature, therapeutic area and the type of licence required (ie where the product is to be sold and whether licences already exist in other EU/EEA Member States). There are also several different legal bases on which an MA application can be made...

This Practice Note examines proposals to enhance the secondary capital raising process for already publicly traded companies, as set out in Mark Austin’s, published in July 2022, and considers how those proposals have since been taken forward. Background Lord Hill’s UK Listing Review, issued in March 2021, set out a series of recommendations to strengthen the UK’s appeal as an IPO venue and to optimise capital-raising processes for companies on UK markets. Among these was a recommendation to explore how to make further capital raising by listed companies more efficient. This was launched in October 2021, when HM Treasury appointed Mark Austin to lead an independent review of the UK’s secondary capital raising processes. Mark Austin chairs the Financial Conduct Authority’s (FCA) Listing Authority Advisory Panel. As outlined in the government’s Terms of Reference, the review’s objective was to make recommendations to improve capital-raising processes for existing publicly traded companies. The work included consideration of improvements to structures such as rights issues, under which shares are offered to...

This Practice Note summarises the principal proposals to overhaul the UK listing regime set out in Lord Hill’s report of 3 March 2021, and outlines how the government and the FCA are progressing those proposals. For more on changes to the listing and prospectus framework, see Practice Notes: Reform of the UK listing regime—fundamentals UK prospectus regime reform The public offers and admissions to trading regime (POATRs)—fundamentals UK Secondary Capital Raising Review UK listing and prospectus regime reform—progress tracker —call for evidence On 19 November 2020, ahead of the end of the Brexit implementation period, HM Treasury opened a review of the UK listing regime to be led by Lord Hill, a former EU financial services commissioner. The process began with a Call for Evidence inviting market participants’ views on five core topics: free float requirements, dual class share structures, track record conditions, prospectuses, and dual and secondary listings. Broader observations on how the UK’s capital markets could attract more...